Nureca revises capex approval to ₹128 Cr for FY26
Nureca Limited reported a net profit of ₹0.71 Cr for FY26 on revenue of ₹31.70 Cr, while recording a net loss of ₹0.70 Cr in Q4FY26. The Board corrected its approval for incremental capital expenditure to ₹128 Cr, up from ₹100 Cr, for manufacturing expansion in Punjab. Additionally, the company announced CFO changes and director reappointments subject to shareholder approval.
*this image is generated using AI for illustrative purposes only.
Nureca Limited reported a net profit of ₹0.71 Cr for the financial year ended March 31, 2026, on total income from operations of ₹31.70 Cr. For the quarter ended March 31, 2026, the company recorded a net loss of ₹0.70 Cr on revenue of ₹31.70 Cr. The Board of Directors approved the audited financial results on May 29, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Financial Performance
The company’s earnings per share (EPS) for the year stood at ₹0.33, calculated on a face value of ₹10 per share. In Q4FY26, the EPS was (₹0.20). The full format of the audited financial results is available on the BSE website and the company's official website.
| Metric (₹ Cr) | Quarter Ended 31.03.2026 (Audited) | Year Ended 31.03.2026 (Audited) |
|---|---|---|
| Total Income from Operations | 31.70 | 31.70 |
| Net Profit / (Loss) | (0.70) | 0.71 |
| Earnings Per Share (₹) | (0.20) | 0.33 |
Board Decisions and Appointments
The Board approved an incremental capital expenditure of up to ₹128 Cr in plant and machinery for manufacturing additional medical devices, healthcare consumables, and hygiene products at its existing industrial land in Sundran, Dera Bassi, Punjab. The Board also approved the purchase of additional land adjoining the existing site for future expansion. This figure corrects a previous disclosure of ₹100 Cr due to a typographical error. M/s. MGSG and Associates were reappointed as Internal Auditor for FY26-27.
Mr. Naresh Gupta resigned as Chief Financial Officer and Key Managerial Personnel effective from the close of business hours on June 26, 2026, to pursue better career opportunities. Consequently, Mr. Chander Kant has been appointed as the new Chief Financial Officer effective June 27, 2026. Mr. Kant brings over 13 years of experience in finance and taxation.
Director Reappointments
The Board approved the reappointment of Mr. Aryan Goyal as Whole-time Director for a further period of three years w.e.f. May 28, 2027, and Mr. Saurabh Goyal as Managing Director for a further period of three years w.e.f. September 03, 2026. Both reappointments are subject to shareholder approval at the ensuing Annual General Meeting. Additionally, Ms. Smita Goyal was appointed as an Additional Director (Whole Time Director) for three years w.e.f. June 01, 2026, subject to shareholder approval.
Historical Stock Returns for Nureca
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.17% | -13.21% | -10.98% | -20.27% | -11.57% | -84.52% |
How will the ₹128 Cr capital expenditure impact Nureca's production capacity and revenue growth in the next fiscal year?
What strategies will the new CFO, Mr. Chander Kant, implement to address the quarterly net loss and improve profitability?
What are the expected timelines for the expansion projects at the Sundran, Dera Bassi site, and when will they become operational?
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
